Alphamab Oncology (HK:9966) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alphamab Oncology has announced the approval of a phase I/II clinical trial for their innovative drug JSKN033, a subcutaneous co-formulation targeting HER2 and PD-L1, by the Center for Drug Evaluation in China. This trial aims to test the safety and efficacy of the drug in patients with advanced metastatic tumors. The company’s advancements in biopharmaceutical technology continue to position them as leaders in oncology drug development.
For further insights into HK:9966 stock, check out TipRanks’ Stock Analysis page.